Comparison of Lobeglitazone With Pioglitazone as Initial Triple Therapy for Diabetes Management
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 190 participants.
Also called NCT02315287
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 190 participants
- Registry
-
NCT02315287
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Unknown status
Technical summary
Registry record NCT02315287. Randomized; triple masking; primary purpose treatment. Start 2014-09 (actual); primary completion 2021-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparison of Lobeglitazone With Pioglitazone as Initial Triple Therapy for Diabetes Management
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Pioglitazone
- Intervention (Drug)
- Lobeglitazone
- Lead sponsor
- Seoul National University Bundang Hospital
Record details
- Record id
cardio:ct-nct02315287- Content hash
f7a7db3aaea1d3e86d4a9950d8f2d89fd4c83a200274b85c36d1e5f5bd7d0ae4